BioVolutions signs LOI with Apredica Inc.
October 1st, 2008
BioVolutions signs LOI with Apredica Inc. to complement its formulation
expertise with Apredica's ADME and Toxicology know-how
BioVolutions signs contract with NuCryst Pharmaceuticals
November 2006 - BioVolutions signs contract with NuCryst Pharmaceuticals
for the development of topical formulations including nanocrystalline
silver, a proprietary nanoparticulate API of NuCryst Pharmaceuticals. "We
are delighted to have BioVolutions' highly dedicated team help
us formulate such a complex system", says President and
CEO Scott Gillis.
|
